Compare · HCWB vs NVO
HCWB vs NVO
Side-by-side comparison of HCW Biologics Inc. (HCWB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HCWB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 34883.3x HCWB ($6.4M).
- Over the past year, HCWB is down 84.5% and NVO is down 21.8% - NVO leads by 62.8 points.
- HCWB has been more active in the news (7 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for HCWB).
- Company
- HCW Biologics Inc.
- Novo Nordisk A/S
- Price
- $4.05-5.92%
- $50.31-2.25%
- Market cap
- $6.4M
- $222.81B
- 1M return
- -40.19%
- +15.47%
- 1Y return
- -84.53%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 7
- 5
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HCWB
- SEC Form POS AM filed by HCW Biologics Inc.
- HCW Biologics Inc. filed SEC Form 8-K: Other Events
- HCW Biologics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
- HCW Biologics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
- SEC Form EFFECT filed by HCW Biologics Inc.
- Amendment: SEC Form S-1/A filed by HCW Biologics Inc.
- HCW Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S